Abstract
Despite local therapy with curative intent, a substantial proportion of patients with invasive transitional cell carcinoma (TCC) of the bladder develop distant metastases during the course of their illness. Furthermore, a subset of patients presents with advanced disease at the time of initial diagnosis. Once the cancer is metastatic, the majority of patients succumb to their disease. As a result, intense efforts over the past two decades have focused on the development of active chemotherapeutic regimens for this disease.
| Original language | English |
|---|---|
| Title of host publication | Urological Oncology |
| Publisher | Springer |
| Pages | 377-389 |
| Number of pages | 13 |
| ISBN (Print) | 9781846283871 |
| DOIs | |
| State | Published - 2008 |
| Externally published | Yes |